Aspen Shares Nosedive 15% on JSE After Shock Profit Warning
Aspen Pharmacare shares see a sharp decline on the JSE following an alarming profit warning. What does it mean for investors?
Adcock Ingram Reports Flat Profit Despite Winter Surge
Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.
Clicks Value Reaches New Heights in Retail Sector
Discover the impressive rise of Clicks value as it nears R100 billion, outpacing Dis-Chem in market valuation.
Life Healthcare Declares 235c Dividend for Investors
Life Healthcare announces a special cash dividend following the successful R13.9 billion sale of its LMI division.
Bidvest’s Role in Adcock Ingram Takeover Bid
Learn how Bidvest's partnership with Natco Pharma impacts Adcock Ingram and shareholder rights amid a new takeover bid.
Adcock Ingram to Delist Amidst Corporate Changes
Adcock Ingram is set to delist from the JSE as Natco Pharma partners with Bidvest in a major take-private deal.
Dis-Chem Grapples with Retail Squeeze and Fierce Competition
The group identifies limited availability of profitable locations as a key risk to its expansion strategy, which relies on opening new stores and acquiring independent pharmacies.
Investing in Hospitals: A Risk Worth Taking
Explore the potential returns of investing in hospitals and the impact on healthcare innovation and access.
Clicks Group: The Value Behind the Price Tag
Clicks Group is undeniably a powerhouse on the JSE. It is widely recognised as a well-managed and resilient business. However, a persistent question dogs potential investors, particularly those inclined towards scepticism: is Clicks Group simply too expensive to justify buying? While it’s true that Clicks trades at a premium compared to many other retailers, this…...
Aspen Pharmacare Manufacturing Dispute Shrouded in Mystery
Explore the Aspen Pharmacare manufacturing dispute and its potential impact on core earnings for the 2025 financial year.